{"id":3828,"date":"2019-05-14T07:00:00","date_gmt":"2019-05-14T07:00:00","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/kallelse-till-arsstamma\/"},"modified":"2019-05-14T07:00:00","modified_gmt":"2019-05-14T07:00:00","slug":"kallelse-till-arsstamma","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/kallelse-till-arsstamma\/","title":{"rendered":"Kallelse till \u00e5rsst\u00e4mma"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<p><span>Aktie\u00e4garna i<\/span><\/p>\n<p><span>Nanexa AB (publ)<\/span><\/p>\n<p><span>kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, tisdagen den 11 juni 2019, klockan 17.00 p\u00e5 Uppsala Business Park, Rapsgatan 7, Uppsala.<\/span><\/p>\n<p><span>A. R\u00e4tt att delta p\u00e5 \u00e5rsst\u00e4mman<\/span><\/p>\n<p><span>Aktie\u00e4gare som \u00f6nskar delta vid st\u00e4mman ska dels vara inf\u00f6rd i den av Euroclear Sweden AB f\u00f6rda aktieboken tisdagen den 4 juni 2019, dels anm\u00e4la sin avsikt att delta i bolagsst\u00e4mman senast fredagen den 7 juni 2019 under adress: Nanexa AB, Virdings All\u00e9 32 B, 754 50 Uppsala, via e-post till info@nanexa.se eller per telefon 018-100 300.<\/span><\/p>\n<p><span>Vid anm\u00e4lan ska aktie\u00e4garen uppge namn, person- eller organisationsnummer, adress, telefonnummer, e-postadress, eventuella bitr\u00e4den samt uppgifter om aktieinnehav. Aktie\u00e4gare som f\u00f6retr\u00e4ds genom ombud ska utf\u00e4rda dagtecknad fullmakt f\u00f6r ombudet. Fullmaktsformul\u00e4r h\u00e5lls tillg\u00e4ngligt p\u00e5 bolagets hemsida www.nanexa.com. Aktie\u00e4gare som har sina aktier f\u00f6rvaltarregistrerade genom banks notariatavdelning eller annan f\u00f6rvaltare m\u00e5ste, f\u00f6r att \u00e4ga r\u00e4tt att delta vid st\u00e4mman, tillf\u00e4lligt inregistrera aktierna i eget namn hos Euroclear Sweden AB. S\u00e5dan registrering m\u00e5ste vara genomf\u00f6rd den 4 juni 2019 och f\u00f6rvaltaren b\u00f6r s\u00e5ledes underr\u00e4ttas i god tid f\u00f6re n\u00e4mnda datum. Om fullmakt utf\u00e4rdas av juridisk person ska bestyrkt kopia av registreringsbevis eller motsvarande f\u00f6r den juridiska personen bifogas. Aktie\u00e4gare som f\u00f6retr\u00e4ds genom ombud skall utf\u00e4rda skriftlig och daterad fullmakt f\u00f6r ombudet. Fullmakten f\u00e5r inte vara utf\u00e4rdad tidigare \u00e4n fem \u00e5r f\u00f6re dagen f\u00f6r st\u00e4mman.<\/span><\/p>\n<p><span>B. \u00c4renden p\u00e5 st\u00e4mman<\/span><\/p>\n<p><span>1. \u00d6ppnande av st\u00e4mman<br \/>2. Val av ordf\u00f6rande vid st\u00e4mman<br \/>3. Uppr\u00e4ttande och godk\u00e4nnande av r\u00f6stl\u00e4ngd<br \/>4. Val av en eller tv\u00e5 justeringsm\u00e4n<br \/>5. Pr\u00f6vning av om st\u00e4mman blivit beh\u00f6rigen sammankallad 6. Godk\u00e4nnande av dagordningen<br \/>7. Framl\u00e4ggande av \u00e5rsredovisningen och revisionsber\u00e4ttelsen 8. Verkst\u00e4llande direkt\u00f6rens anf\u00f6rande<br \/>9. Beslut om<\/span><\/p>\n<ol>\n<li>\n<p><span>a) \u00a0fastst\u00e4llelse av resultatr\u00e4kningen och balansr\u00e4kningen<\/span><\/p>\n<\/li>\n<li>\n<p><span>b) \u00a0dispositioner betr\u00e4ffande bolagets vinst eller f\u00f6rlust enligt den fastst\u00e4llda<\/span><\/p>\n<p><span>balansr\u00e4kningen<\/span><\/p>\n<\/li>\n<li>\n<p><span>c) \u00a0ansvarsfrihet f\u00f6r styrelseledam\u00f6terna och den verkst\u00e4llande direkt\u00f6ren<\/span><\/p>\n<\/li>\n<\/ol>\n<p><span>10. Fastst\u00e4llande av arvoden till styrelsen och revisorn<\/span><\/p>\n<p><span>11. Val till styrelsen och av revisor<br \/>12. Beslut om bemyndigande avseende f\u00f6retr\u00e4desemission 13. Beslut om bemyndigande avseende riktad emission14.\u00a0Avslutande av bolagsst\u00e4mman<\/span><\/p>\n<p><span>F\u00f6rslag till beslut<\/span><\/p>\n<p><span>Punkt 12<\/span><\/p>\n<p><span>Styrelsen f\u00f6resl\u00e5r att \u00e5rsst\u00e4mman beslutar att bemyndiga styrelsen att, vid ett eller flera tillf\u00e4llen, f\u00f6r tiden intill n\u00e4sta \u00e5rsst\u00e4mma, fatta beslut om emission av aktier, teckningsoptioner och\/eller konvertibler. Styrelsens beslut f\u00e5r f\u00f6renas med villkor om att tecknade aktier f\u00e5r betalas genom kvittning. Emission skall ske med f\u00f6retr\u00e4de f\u00f6r befintliga aktie\u00e4gare.<\/span><\/p>\n<p><span>Punkt 13<\/span><\/p>\n<p><span>Styrelsen f\u00f6resl\u00e5r att \u00e5rsst\u00e4mman beslutar att bemyndiga styrelsen att, vid ett eller flera tillf\u00e4llen, f\u00f6r tiden intill n\u00e4sta \u00e5rsst\u00e4mma, fatta beslut om emission av aktier, teckningsoptioner och\/eller konvertibler. Styrelsen skall kunna besluta om emission med avvikelse fr\u00e5n aktie\u00e4garnas f\u00f6retr\u00e4desr\u00e4tt och\/eller med best\u00e4mmelse om apport, kvittning eller eljest med villkor. Styrelsen skall dock, med st\u00f6d av detta bemyndigande, inte kunna fatta beslut som inneb\u00e4r att aktiekapitalet \u00f6kas med mer \u00e4n 20 procent i f\u00f6rh\u00e5llande till det aktiekapital som f\u00f6religger n\u00e4r emissionsbemyndigandet f\u00f6rsta g\u00e5ngen tas i anspr\u00e5k.<\/span><\/p>\n<p><span>Sk\u00e4let till att styrelsen skall kunna fatta beslut om emission med avvikelse fr\u00e5n aktie\u00e4gares f\u00f6retr\u00e4desr\u00e4tt och\/eller med best\u00e4mmelse om apport, kvittning eller villkor enligt ovan \u00e4r att bolaget skall kunna emittera aktier, teckningsoptioner och\/eller konvertibler i syfte att inf\u00f6rskaffa nytt kapital samt att m\u00f6jligg\u00f6ra f\u00f6r styrelsen att rikta emissioner till investerare som styrelsen bed\u00f6mer vara strategiskt viktiga f\u00f6r bolaget.<\/span><\/p>\n<p><span>C. Upplysningar, handlingar och antal aktier och r\u00f6ster<\/span><\/p>\n<p><span>Styrelsen och VD ska, om n\u00e5gon aktie\u00e4gare beg\u00e4r det och styrelsen anser att det kan ske utan v\u00e4sentlig skada f\u00f6r bolaget l\u00e4mna upplysningar om f\u00f6rh\u00e5llanden som kan inverka p\u00e5 bed\u00f6mningen av ett \u00e4rende p\u00e5 dagordningen.<\/span><\/p>\n<p><span>Redovisningshandlingar och revisionsber\u00e4ttelse finns tillg\u00e4ngliga p\u00e5 bolagets hemsida, www.nanexa.com, och p\u00e5 bolagets adress Virdings All\u00e9 32 B (bes\u00f6ksadress Rapsgatan 7), 754 50 Uppsala. Kopior av dessa handlingar kommer att s\u00e4ndas till de aktie\u00e4gare som beg\u00e4r det och uppger sin postadress. Handlingarna kommer \u00e4ven att h\u00e5llas tillg\u00e4ngliga vid st\u00e4mman.<\/span><\/p>\n<p><span>Bolaget har 15 159 898 aktier och r\u00f6ster.<\/span><\/p>\n<p><span>F\u00f6r mer information kontakta:<br \/>David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0Telefon: 0709 &#8211; 42 83 03<br \/>E-post: david.westberg@nanexa.sewww.nanexa.com<\/span><\/p>\n<p><span>Om Nanexa AB (publ)<\/span><\/p>\n<p><span>Styrelsen<\/span><\/p>\n<p><span><img alt=\"page3image9144\"\/><\/span><\/p>\n<p><span>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/mb.cision.com\/Main\/12591\/2812399\/1044214.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Read as PDF<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n<p>Aktie\u00e4garna i<\/p>\n<p>Nanexa AB (publ)<\/p>\n<p>kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, tisdagen den 11 juni 2019, klockan 17.00 p\u00e5 Uppsala Business Park,<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/kallelse-till-arsstamma\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3828","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-ci-gm_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-ci-gm-notice_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kallelse till \u00e5rsst\u00e4mma - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kallelse till \u00e5rsst\u00e4mma - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Aktie\u00e4garna i Nanexa AB (publ) kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, tisdagen den 11 juni 2019, klockan 17.00 p\u00e5 Uppsala Business Park,L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma\\\/\",\"name\":\"Kallelse till \u00e5rsst\u00e4mma - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-05-14T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Kallelse till \u00e5rsst\u00e4mma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kallelse till \u00e5rsst\u00e4mma - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/","og_locale":"sv_SE","og_type":"article","og_title":"Kallelse till \u00e5rsst\u00e4mma - Nanexa AB","og_description":"Aktie\u00e4garna i Nanexa AB (publ) kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, tisdagen den 11 juni 2019, klockan 17.00 p\u00e5 Uppsala Business Park,L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/","url":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/","name":"Kallelse till \u00e5rsst\u00e4mma - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-05-14T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Kallelse till \u00e5rsst\u00e4mma"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}